Facing antitrust lawsuit, J&J's Remicade stands firm against biosimilar competition in Q3

17th October 2017 Uncategorised 0

Under a growing biosimilar assault, Johnson & Johnson’s big-selling immunology biologic Remicade held its ground again in the third quarter. Now, executives are planning their 2018 defense strategy for a critical medication that leads sales for the drug giant.

More: Facing antitrust lawsuit, J&J's Remicade stands firm against biosimilar competition in Q3
Source: fierce